Datapoint: Elevance Adds Humira Biosimilars to Commercial Formularies

November 2

Elevance Health Inc.’s CarelonRx PBM will add two of Boehringer Ingelheim’s Humira biosimilars to some of its formularies starting Dec. 1, the firm said on Oct. 19. The move will put those drugs “at parity with Humira,” per a press release. The lower-list-price version of adalimumab-adbm  will be added to all CarelonRx’s commercial formularies, while Boehringer’s Cyltezo will be added to “select” commercial formularies, the press release added. Elevance currently covers 6.17 million commercial lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 10/30/23